P Bjornstad1,2, T Costacou3, R G Miller3, D M Maahs4, M J Rewers1,2, T J Orchard3, J K Snell-Bergeon2. 1. Department of Pediatric Endocrinology, University of Colorado School of Medicine. 2. Barbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO. 3. Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA. 4. Department of Pediatric Endocrinology, Stanford University School of Medicine, Palo Alto, CA, USA.
Abstract
AIM: Diabetic kidney disease is one of the leading complications of Type 1 diabetes, but its prediction remains a challenge. We examined predictors of rapid decline in estimated GFR (eGFR) in two Type 1 diabetes cohorts: the Coronary Artery Calcification in Type 1 Diabetes (CACTI) and the Pittsburgh Epidemiology of Diabetes Complications (EDC). METHODS: A select subset of participants (CACTI: n = 210 and EDC: n = 98) diagnosed before 17 years of age with Type 1 diabetes duration ≥ 7 years, and follow-up data on eGFR by CKD-EPI creatinine for up to 8 years were included in the analyses. Early renal function decline was defined as annual decline in eGFR ≥ 3 ml/min/1.73 m2 , and normal age-related decline as eGFR ≤ 1 ml/min/1.73 m2 . Parallel logistic regression models were constructed in the two cohorts. RESULTS: Early renal function decline incidence was 36% in CACTI and 41% in EDC. In both cohorts, greater baseline eGFR (CACTI: OR 3.12, 95% CI 1.97-5.05; EDC: OR 1.92, 95% CI 1.17-3.15 per 10 ml/min/1.73 m2 ) and log albumin-to-creatinine (ACR) (CACTI: OR 3.24, 95% CI 1.80-5.83; EDC: OR 1.87, 95% CI 1.18-2.96 per 1 unit) predicted greater odds of early renal function decline in fully adjusted models. Conversely, ACE inhibition predicted lower odds of early renal function decline in women in CACTI, but similar relationships were not observed in women in EDC. CONCLUSIONS: A substantial proportion of people with Type 1 diabetes in the EDC and CACTI cohorts experienced early renal function decline over time. ACE inhibition appeared to be protective only in women in CACTI where the prevalence of its use was twofold higher compared with the EDC.
AIM: Diabetic kidney disease is one of the leading complications of Type 1 diabetes, but its prediction remains a challenge. We examined predictors of rapid decline in estimated GFR (eGFR) in two Type 1 diabetes cohorts: the Coronary Artery Calcification in Type 1 Diabetes (CACTI) and the Pittsburgh Epidemiology of Diabetes Complications (EDC). METHODS: A select subset of participants (CACTI: n = 210 and EDC: n = 98) diagnosed before 17 years of age with Type 1 diabetes duration ≥ 7 years, and follow-up data on eGFR by CKD-EPI creatinine for up to 8 years were included in the analyses. Early renal function decline was defined as annual decline in eGFR ≥ 3 ml/min/1.73 m2 , and normal age-related decline as eGFR ≤ 1 ml/min/1.73 m2 . Parallel logistic regression models were constructed in the two cohorts. RESULTS: Early renal function decline incidence was 36% in CACTI and 41% in EDC. In both cohorts, greater baseline eGFR (CACTI: OR 3.12, 95% CI 1.97-5.05; EDC: OR 1.92, 95% CI 1.17-3.15 per 10 ml/min/1.73 m2 ) and log albumin-to-creatinine (ACR) (CACTI: OR 3.24, 95% CI 1.80-5.83; EDC: OR 1.87, 95% CI 1.18-2.96 per 1 unit) predicted greater odds of early renal function decline in fully adjusted models. Conversely, ACE inhibition predicted lower odds of early renal function decline in women in CACTI, but similar relationships were not observed in women in EDC. CONCLUSIONS: A substantial proportion of people with Type 1 diabetes in the EDC and CACTI cohorts experienced early renal function decline over time. ACE inhibition appeared to be protective only in women in CACTI where the prevalence of its use was twofold higher compared with the EDC.
Authors: Allan J Collins; Robert N Foley; Charles Herzog; Blanche Chavers; David Gilbertson; Areef Ishani; Bertram Kasiske; Jiannong Liu; Lih-Wen Mau; Marshall McBean; Anne Murray; Wendy St Peter; Haifeng Guo; Sally Gustafson; Qi Li; Shuling Li; Suying Li; Yi Peng; Yang Qiu; Tricia Roberts; Melissa Skeans; Jon Snyder; Craig Solid; Changchun Wang; Eric Weinhandl; David Zaun; Cheryl Arko; Shu-Cheng Chen; Frederick Dalleska; Frank Daniels; Stephan Dunning; James Ebben; Eric Frazier; Christopher Hanzlik; Roger Johnson; Daniel Sheets; Xinyue Wang; Beth Forrest; Edward Constantini; Susan Everson; Paul Eggers; Lawrence Agodoa Journal: Am J Kidney Dis Date: 2011-01 Impact factor: 8.860
Authors: Petter Bjornstad; David Z Cherney; Janet K Snell-Bergeon; Laura Pyle; Marian Rewers; Richard J Johnson; David M Maahs Journal: Nephrol Dial Transplant Date: 2015-06-06 Impact factor: 5.992
Authors: Lesley A Inker; Christopher H Schmid; Hocine Tighiouart; John H Eckfeldt; Harold I Feldman; Tom Greene; John W Kusek; Jane Manzi; Frederick Van Lente; Yaping Lucy Zhang; Josef Coresh; Andrew S Levey Journal: N Engl J Med Date: 2012-07-05 Impact factor: 91.245
Authors: David M Maahs; Diana Jalal; Kim McFann; Marian Rewers; Janet K Snell-Bergeon Journal: Clin J Am Soc Nephrol Date: 2011-07-22 Impact factor: 8.237
Authors: Sarah Stark Casagrande; Judith E Fradkin; Sharon H Saydah; Keith F Rust; Catherine C Cowie Journal: Diabetes Care Date: 2013-02-15 Impact factor: 19.112
Authors: Andrzej S Krolewski; Monika A Niewczas; Jan Skupien; Tomhito Gohda; Adam Smiles; Jon H Eckfeldt; Alessandro Doria; James H Warram Journal: Diabetes Care Date: 2013-08-12 Impact factor: 19.112
Authors: Bruce A Perkins; Ionut Bebu; Xiaoyu Gao; Amy B Karger; Irl B Hirsch; Harsha Karanchi; Mark E Molitch; Bernard Zinman; John M Lachin; Ian H de Boer Journal: Diabetes Care Date: 2022-03-01 Impact factor: 19.112
Authors: Antonio Mirijello; Francesca Viazzi; Paola Fioretto; Carlo Giorda; Antonio Ceriello; Giuspina T Russo; Pietro Guida; Roberto Pontremoli; Salvatore De Cosmo Journal: BMC Nephrol Date: 2018-12-04 Impact factor: 2.388